SkyePharma Plc (SKYEY.PK,SKP.L) announced that the SkyePharma Group has entered into a consultation process which could lead to a reduction of nearly 20% of its 101-strong workforce in Muttenz, Switzerland. The company noted that the proposed steps are planned to improve its competitiveness and generate CHF 2.6 million or 1.8 million pounds of operating cost savings each year.
Separately, the Group reached deals with the Aenova Group to sub-let part of its laboratory space in Muttenz and sell some of its surplus laboratory equipment to Aenova. Aenova intends to use the space to expand its own non-competing oral product development activities and has agreed to consider offering positions to some of the SkyePharma employees potentially affected by the headcount reduction.
The changes would not affect relationships with existing or potential customers and the Group would continue to provide its full existing range of innovative oral and inhalation drug delivery solutions.
In future, SkyePharma plans to make greater use of third-party sub-contracting for certain aspects of the oral product development process and Aenova has agreed to be a sub-contractor for this purpose. There would be no transfer or disposal of any business, technology or intellectual property to Aenova and Aenova's oral product development activities do not directly compete with those of SkyePharma.
 | | To receive FREE breaking news email alerts for SkyePharma Plc and others in your portfolio |
|
by RTT Staff Writer
For comments and feedback: editorial@rttnews.com
Business News